An Interventional, Multicenter, and International Phase 1/2, Light-dose-escalation Study to Investigate the Safety and Feasibility of Intraoperative Photodynamic Therapy (PDT) With Pentalafen® Drug and Heliance® Solution Device in Male and Female Patients 18 to 75 Years of Age With Grade IV Glioblastoma.
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Hemerion Therapeutics
- Enrollment
- 12
- Locations
- 4
- Primary Endpoint
- MTD, which will be assessed on the basis of number of patients with DLT.
Study Overview
Brief Summary
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 75 with newly diagnosed glioblastoma.
This treatment will be carried out in addition to the maximal surgical resection. Data collected during this trial will be used to design the upcoming pivotal study .
The study will utilize an independent Data and Safety Monitoring Board (iDSMB) that will review safety data to allow dose escalation.
Detailed Description
This study is a non randomized, open label, multicentercenter , phase 1/2 trial with a sequential enrollment in a 3+3 dose escalation design to establish the maximal tolerated dose of light (MTD).
The dose of light will be escalated in successive cohorts of patients until at least 1 patient experiences a dose-limiting toxicity (DLT).
A DLT is defined as any grade ≥ 3 Adverse Event (AE), or any relevant grade 2 AE of Central Nervous System or any Serious Adverse Events (SAEs) possibly, probably or definitively related to the intraoperative PDT (i.e., 5-aminolevulinic acid hydrochloride (5-ALA HCl) administration + brain cavity illumination), for which the onset date is within 28 days after the procedure, and where conservative therapy fails and surgical is required, according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
After dose escalation patient will be followed in the standard of care until visit at 6 months to evaluate the progression free survival.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males or females must be between 18, or legal age of consent, and 75 years of age (both included) at the time of signing informed consent.
- •Signed informed consent which includes compliance with requirements and restrictions listed in the informed consent.
- •Newly diagnosed GBM, presumed on the basis of clinical and MRI criteria (intra-axial brain tumor with peripheral rim contrast enhancement).
- •Karnofsky Performance Score ≥70 I
- •Eligible for surgery. I
- •Amenable to maximal tumor resection based on MRI. I
- •Planned to receive SOC (i.e., Stupp Protocol) treatment after surgery. I
- •Ability to take oral medications. I
- •Tumor eligible to PDT procedure as validated by both investigator and sponsor based on pre-operative MRI data
Exclusion Criteria
- •1.Medical conditions E
- •Patient with bifocal or multifocal disease, assessed on MR1I T1Gd enhanced.
- •Patient with tumor of deep location such as tumor involving the corpus callosum, the basal ganglia, the brain stem, or tumor involving the midline as assessed on MRI.
- •Patient with prior brain surgery other than stereotactic biopsy E
- •Patient with Lynch syndrome E
- •Patient with Li-Fraumeni syndrome E
- •Debilitating cardiopulmonary disease, unstable Type 1 or Type 2 diabetes (treated or not) E
- •History or current condition of another malignancy (excluding basal cell carcinoma, or E
- •carcinoma in-situ) unless treated and off all active therapy for more than 5 years E
- •Clinically significant abnormal ECG results, including a corrected QT interval QTc > 480 ms E
- •Creatinine clearance < 60 mL/min E
- •Severe hepatic impairment (bilirubin > 1.5 x the upper limit of normal [ULN] or alkaline phosphatase or transaminases (AST, ALT) > 2.5 x ULN) E
- •Known allergic reactions to silicone E
- •Known allergic reactions or hypersensitivity to egg, soya, or peanut proteins.
- •Febrile illness
- •Contraindication
- •Contraindication to 5-ALA HCl administration, including:
- •Taking photosensitizing drugs 24 hours before and 14 days after the administration of Pentalafen® including but not limited to: St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines, and topical preparations containing ALA (See Section 6.10)
- •Inability to suspend a long-term hepatotoxic treatment (such as, but not limited to diclofenac, fenofibrate, carbamazepine) for 24 hours after 5-ALA HCl intake E
- •Contraindication to MRI examination (e.g., MRI-incompatible pacemaker) E
- •Treatment with another investigational drug or intervention within 30 days prior to or during the entire study
Outcomes
Primary Outcomes
MTD, which will be assessed on the basis of number of patients with DLT.
MTD, which will be assessed on the basis of number of patients with DLT.
Secondary Outcomes
- Score of device usability calculated from usefulness, ease of use, ease of learning and satisfaction/intention of use measures.
- PFS6, defined as the interval (in days or months) from intraoperative PDT to the date of first detection of progressive disease.
- Number of AEs and SAEs
Investigators
Maximilien Vermandel
Scientific
Hemerion Therapeutics